Detection and Diagnosis of Pancreatic Cancer

胰腺癌的检测和诊断

• 批准号: 6915870
• 负责人: DAVID V GOLD
• 金额: $ 26.62万
• 依托单位: CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-09 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6915870
• 关键词: antigen antibody reaction; athymic mouse; biomarker; cell line; clinical research; diagnosis design /evaluation; early diagnosis; enzyme activity; glycosidases; glycosyltransferase; human tissue; immunocytochemistry; microarray technology; monoclonal antibody; mucins; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunology; oligosaccharides; pancreas neoplasms; posttranslational modifications; protein quantitation /detection; tumor antigens; xenotransplantation

DESCRIPTION (provided by applicant): Pancreatic cancer is one of the most insidious forms of cancer. Recent estimates of new cancer cases put pancreatic cancer at eighth and ninth among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Due largely to the location, and silent growth of the tumor, most patients present at a time when it is too late to undergo any realistic type of curative treatment. This has translated into a 5-year survival rate of less than 3%. In a recent report, "Pancreatic Cancer: An Agenda for Action", the NCI's Pancreatic cancer Progress Review Group drew specific attention to the urgent need for "better screening and diagnostic techniques" with a recommendation to "delineate and validate effective molecular biomarkers" for pancreatic cancer. With this in mind, we intend to develop and assess the utility of a PAM4, anti-MUC1 antibody-based immunoassay to detect, diagnose, and provide for the management of this disease. Although there have been several reports concerning anti-MUC1 MAbs reactive with several types of cancer, PAM4 appears to be unique, or nearly so, in terms of its specificity and the molecular characteristics of the epitope to which it is reactive. The long-term objective of this proposal is to identify specific biomarkers that can be combined with the PAM4 assay for enhanced diagnostic accuracy of pancreatic cancer. The specific aims of this proposal are Aim 1. To investigate the diagnostic accuracy of an immunoassay for the quantitation of PAM4-reactive MUC1 in biological fluids as a means for early detection and diagnosis of pancreatic cancer. Aim 2. To investigate the heterogeneity in expression of MUC1 epitope structures as a means to identify patterns that may be organ and/or tumor "specific/associated". Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses.

描述(申请人提供)：胰腺癌是最隐蔽的癌症之一。最近对新发癌症病例的估计显示，胰腺癌在女性和男性中分别位居第八和第九。然而，它是女性和男性所有癌症死亡的第四大原因，仅次于肺癌、结直肠癌、前列腺癌和乳腺癌。很大程度上由于肿瘤的位置和沉默的生长，大多数患者出现在为时已晚的时候，无法接受任何现实类型的治疗。这意味着5年存活率不到3%。在最近的一份题为《胰腺癌：行动议程》的报告中，NCI的胰腺癌进展回顾小组特别注意到迫切需要“更好的筛查和诊断技术”，并建议“描绘和验证有效的胰腺癌分子生物标记物”。考虑到这一点，我们打算开发和评估一种基于PAM4、抗MUC1抗体的免疫分析方法来检测、诊断和治疗这种疾病。虽然已经有一些关于抗MUC1单抗与几种类型的癌症反应的报道，但PAM4在其特异性和与其反应的表位的分子特征方面似乎是独一无二的，或者说几乎是独一无二的。这项建议的长期目标是确定特定的生物标记物，可以与PAM4检测相结合，以提高胰腺癌的诊断准确性。本建议的具体目的是：1.探讨免疫测定法测定体液中PAM4反应性MUC1作为胰腺癌早期诊断手段的诊断准确性。目的2.研究MUC1表位结构表达的异质性，以此为手段识别可能与器官和/或肿瘤“特异/相关”的模式。目的3.通过多因素分析研究是否包括其他粘蛋白生物标志物可以提高诊断的准确性。